依托泊苷与异环磷酰胺治疗对美法仑和泼尼松（MP）及长春新碱、阿霉素和地塞米松（VAD）耐药的浆细胞骨髓瘤：一例报告
Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
作者信息
Ikeda K, Abe N, Morioka A, Inoo M, Nagai M, Kubota Y, Irino S
机构信息
First Department of Internal Medicine, Kagawa Medical School, Japan.
出版信息
Jpn J Med. 1990 Sep-Oct;29(5):516-8. doi: 10.2169/internalmedicine1962.29.516.
A patient with plasma cell myeloma refractory to both MP (melphalan-prednisolone) and VAD (vincristine-adriamycin-dexamethasone) was treated with a combination chemotherapy consisting of VP-16, ifosfamide and dexamethasone (VID). A partial remission of 12-month duration was achieved. VID combination might be considered for myeloma patients who are refractory to both MP and VAD, and not eligible for high-dose melphalan with bone marrow transplantation.
一名对MP（美法仑-泼尼松）和VAD（长春新碱-阿霉素-地塞米松）均耐药的浆细胞骨髓瘤患者接受了由VP-16、异环磷酰胺和地塞米松（VID）组成的联合化疗。获得了持续12个月的部分缓解。对于对MP和VAD均耐药且不符合大剂量美法仑联合骨髓移植条件的骨髓瘤患者，可考虑使用VID联合方案。
Zotero 插件